<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04120987</url>
  </required_header>
  <id_info>
    <org_study_id>IIR-USA-002133</org_study_id>
    <nct_id>NCT04120987</nct_id>
  </id_info>
  <brief_title>Ocular Inflammation in Cataract Patients and Response to Treatment With Xiidra</brief_title>
  <official_title>The Incidence of Ocular Inflammation as Defined by the Inflammadry Assay in 250 Consecutive Cataract Patients and Their Response to Treatment With Xiidra</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bucci Laser Vision Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bucci Laser Vision Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if the use of Xiidra® reduces ocular surface inflammation in preoperative and
      postoperative cataract patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single-center, prospective, randomized, investigator-initiated study

      250 cataract patients, aged 60 or older, will be tested for ocular surface inflammation with
      the InflammaDry® immunoassay

      Patients with bilateral positive MMP-9 will be randomized into a group treated with Xiidra
      two weeks preoperatively and six weeks postoperatively or a group not treated with Xiidra

      The investigator hypothesizes that treatment with Xiidra prior to routine cataract surgery
      will significantly improve the quality of keratometry readings and BCVA.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">September 25, 2019</start_date>
  <completion_date type="Anticipated">September 25, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 25, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the conversion rates of bilateral positive MMP-9 to negative in pre-cataract and post-cataract patients receiving treatment with Xiidra versus no Xiidra</measure>
    <time_frame>12 weeks</time_frame>
    <description>Compare the conversion rates of bilateral positive MMP-9 to negative in pre-cataract and post-cataract patients receiving treatment with Xiidra versus no Xiidra</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>Lifitegrast</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One drop of Lifitegrast Ophthalmic Solution 5% will be instilled into each eye twice daily (approximately 12 hours apart) using a single-use conainer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lifitegrast 5% Ophthalmic Solution</intervention_name>
    <description>BID OU</description>
    <arm_group_label>Lifitegrast</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Positive for MMP-9 bilaterally as assessed by the Inflammadry assay

        Exclusion Criteria:

          -  Negative Inflammadry assay in either eye

          -  Active diabetic retinopathy, uncontrolled glaucoma, uncontrolled uveitic inflammation

          -  Ocular surface diseases that might confound the interpretation of the InflammaDry
             assay
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank A Bucci, Jr., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bucci Laser Vision</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bucci Laser Vision</name>
      <address>
        <city>Wilkes-Barre</city>
        <state>Pennsylvania</state>
        <zip>18702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>September 25, 2019</study_first_submitted>
  <study_first_submitted_qc>October 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2019</study_first_posted>
  <last_update_submitted>October 7, 2019</last_update_submitted>
  <last_update_submitted_qc>October 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cataract</keyword>
  <keyword>lifitegrast</keyword>
  <keyword>dry eye syndrome</keyword>
  <keyword>ocular surface inflammation</keyword>
  <keyword>hyperosmolarity</keyword>
  <keyword>MMP-9</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Lifitegrast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

